Pharmacologic treatments for covid-19 patients

Colchicine vs Standard care/Placebo

This comparison will not be updated. Last search date 28 Feb, 2022.


Outpatients

Forest plots
(last update: 2022-04-29)

Summary of findings
(last update: 2022-04-27)

Hospitalized patients

Forest plots
(last update: 2022-04-15)

Summary of findings
(last update: 2022-05-09)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=30

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
N/A
Alsultan M, Interdiscip Perspect Infect Dis, 2021
Full text
Commentary
Not reported/unclear

Colchicine

Budesonide

Colchicine

Standard care

Standard care

Budesonide

RCT Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to a single center in Syria. N=49 N/A

Full description

NCT04328480
ECLA PHRI COLCOVID
Diaz R, JAMA Netw Open, 2021
Full text
Commentary
Commentary
Mixed

Colchicine

Standard care

RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 42 centers in Argentina. N=1279
Some concerns
Details

Full description

NCT04367168
COLCHIVID
Absalon-Aguilar A, J Gen Intern Med, 2021
Full text
Commentary
Public/non profit

Colchicine

Placebo

RCT Patients with confirmed COVID-19 (severe) admitted to 2 centers in Mexico N=116
Some concerns
Details

Full description

NCT04724629
Bonifacio L, Antimicrob Resist I, 2021
Full text
Public/non profit

Ixekizumab

Interleukin-2

Colchicine

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in Brazil. N=30
Some concerns
Details

Full description

ISRCTN86534580
PRINCIPLE
Dorward J, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit

Colchicine

Standard care

RCT Outpatients with suspected or confirmed COVID-19 (symptomatic) treated at multiple primary care centers or at home in the UK. N=276
Some concerns
Details

Full description

NCT04350320 ; EUDRACT 2020-001511-2
COL-COVID
Pascual-Figal DA, Int J Gen Med, 2021
Full text
Commentary
Public/non profit

Colchicine

Standard care

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to hospital in Spain. N=103
Some concerns
Details

Full description

NCT04381936 ; ISRCTN50189673
RECOVERY (COL)
Horby P, medRxiv, 2021
Full text
Commentary
Commentary
Mixed

Colchicine

Standard care

RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 177 centers in the UK, 2 centers in Indonesia, and 2 centers in Nepal N=11340
Some concerns
Details

Full description

NCT04322682
COLCORONA
Tardif JC, Lancet Respir Med, 2021
Full text
Commentary
Commentary
Mixed

Colchicine

Placebo

RCT Outpatients with suspected or confirmed COVID-19 (mild) at multiple centers in Brazil, Canada, Greece, South Africa, Spain, USA N=4488
Some concerns
Details

Full description

IRCT20200418047126N1
Salehzadeh F, Research Square, 2020
Full text
Commentary
Public/non profit

Colchicine

Placebo

RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Iran N=100
Some concerns
Details

Full description

RBR-8jyhxh
Lopes MIF, RMD Open, 2021
Full text
Commentary
Public/non profit

Colchicine

Placebo

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Brazil N=75
Some concerns
Details

Full description

NCT04326790
Deftereos S, JAMA, 2020
Full text
Commentary
Private

Colchicine

Standard care

RCT Patients with COVID-19 (moderate-severe) admitted to 16 centers in Greece. N=110
Some concerns
Details

Full description